You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
None
Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targ...
The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.
This issue of Hematology/Oncology Clinics, guest edited by Patrick A. Ott, will focus on Immunotherapy in Cancer. Topics include, but are not limited to, Cancer Vaccines, Innate Immune stimulation, Costimulatory and Agonistic Antibodies, Immune modulation with radiation, Oncolytic virus therapy, Cytokine Therapy, Adoptive T cell transfer, Immune related toxicity, and Immune checkpoint combinations.
This two part issue of Oral and Maxillofacial Surgery Clinics of North America is devoted to The Head and Neck Cancer Patient. Part II focuses on Treatment, and is edited by Drs. Zvonimir Milas and Thomas D. Schellenberger. Articles will include: Laryngeal Cancer; Oral Cavity Cancer; Radiation Oncology in Head and Neck Cancer: Current Standards and Future Changes; Soft Tissue Reconstruction of the Head and Neck; Neck Dissection; Principles of immunotherapy of head and neck cancer; Osseous Reconstruction for Head and Neck Patients; Gene Therapy and the Future of Head and Neck Oncology; Management of Oropharyngeal Cancer: Multimodality Treatment; Salivary Gland Malignancies; Current Concepts in Chemotherapy for Head and Neck Cancer; and more!
None